# Andrew J. Armstrong

Source: https://onco.cc/people/andrew-armstrong/  
OnCo record `andrew-armstrong` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer.

## Summary

Andrew Armstrong was principal investigator of ARCHES, the trial showing enzalutamide plus androgen deprivation improves radiographic progression-free and overall survival in metastatic hormone-sensitive prostate cancer, and led the PROPHECY study validating AR-V7 in circulating tumour cells as a marker of resistance to AR inhibitors. He directs prostate cancer research at Duke.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: prostate; trialist
- Role: Professor of Medicine, Surgery, and Pharmacology and Cancer Biology, Duke Cancer Institute
- Specialisms: Prostate cancer; Androgen receptor inhibitors; Biomarkers of resistance; Circulating tumour cells

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Armstrong%20AJ%5BAuthor%5D%20enzalutamide%20ARCHES

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- institutions: [Duke Cancer Institute](https://onco.cc/institutions/duke-cancer-institute/)
- trials: [ARCHES](https://onco.cc/trials/arches/)

---
JSON: https://onco.cc/api/v1/entities/andrew-armstrong.json